Administration of additional inactive iodide during radioiodine therapy for Graves' disease: Who might benefit?

NuklearMedizin

Volumn 46, Issue 3, 2007, Pages 77-84

  Dietlein, M ^a   Moka, D ^a   Reinholz, U ^a   Schmidt, M ^a   Schomacker K ^a   Schicha, H ^a   Wellner, U ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Dosimetry; Graves' disease; Half life; Iodide; Radioiodine therapy

Indexed keywords

LIOTHYRONINE; POTASSIUM IODIDE; RADIOACTIVE IODINE; THYROXINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; FEMALE; GRAVES DISEASE; HUMAN; MALE; RADIATION DOSE; RADIOIMMUNOASSAY; THYROID FUNCTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIBODIES; COMBINED MODALITY THERAPY; FEMALE; GRAVES DISEASE; HUMANS; IODIDE PEROXIDASE; IODIDES; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RECEPTORS, THYROTROPIN; REFERENCE VALUES; THYROTROPIN; TRIIODOTHYRONINE;

EID: 34249933403     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1160/nukmed-0045     Document Type: Article

References (29)

1. 131I used in the treatment of hyperthyroid patients with Graves' disease. Nuklearmedizin 2005; 44: 197-199.
2. Chiovato L, Fiore E, Vitti P et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998; 83: 40-46.
3. Delange F, Dunn JT, Glinoer D. Requirements of iodine in humans. In: Delange F, Dunn JT, Glinoer D (eds). Iodine Deficiency in Europe. New York: Plenum Press 1993; 5.
4. Dietlein M, Dressler J, Eschner W et al. Verfahrensanweisung zum Radioiodtest (Version 2). Nuklearmedizin 2003; 42: 116-119.
5. Dietlein M, Dressler J, Grünwald F et al. Leitlinie zur Radioiodtherapie bei benignen Schilddrüsenerkrankungen (Version 3). Nuklearmedizin 2004; 43: 217-220.
6. Dietlein M, Kobe C, Schmidt M et al. The incidentaloma of the thyroid: Over- or underuse of diagnostic procedure for an epidemiologic finding? Nuklearmedizin 2005; 44: 213-224.
7. Dietlein M, Dederichs B, Kobe C et al. Therapy for non-toxic multinodular goiter. Nuklearmedizin 2006; 45: 27-34.
8. Dunkelmann S, Neumann V, Staub U et al. Results of a risk adapted and functional radioiodine therapy in Graves' disease. Nuklearmedizin 2005; 44: 238-242.
9. 99mTc-uptake in autonomous thyroid tissue in Germany since the 1970s. Nuklearmedizin 2006; 45: 122-125.
10. Hao ST, Reasner II CA, Becker RA. Use of cold iodine in patients with Graves' disease. Observations from a clinical practice. Endocr Pract 2001; 7: 438-442.
11. Howarth D, Epstein M, Lan L et al. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Eur J Nucl Med 2001; 28: 1489-1495.
12. Jonckheer MH, Flamen P, Velkeniers B et al. Radioiodine turnover studies as a mean to predict stable intrathyroidal iodine stores and comments upon its use in the diagnosis and treatment of hyperthyroidism. Thyroid 1993; 3: 11-16.
13. Koch W, Rosa F, Knesewitsch P et al. Guideline on radiation protection in medicine requires documentation of radioiodine therapy and follow-up: What are the benefits of an electronic database? Nuklearmedizin 2005; 44: 49-55.
14. Marinelli LD, Quimby EH, Hine GJ. Dosage determination with radioactive isotopes. Am J Roentgenol 1948; 59: 260-281.
15. 131I activities and radioiodine therapy. Nuklearmedizin 2005; 44: 243-248.
16. 131I-induced release of "cold" iodine stored in the thyroid. Nuklearmedizin 2005; 44: 137-142.
17. Pfannenstiel P, Hotze L-A, Saller B. Schilddrüsenkrankheiten. Diagnose und Therapie. Berlin: Berliner Medizinische Verlagsanstalt 1999; 21-36.
18. Reiners Chr, Hänscheid H, Lassmann M et al. X-ray fluorescence analysis (XFA) of thyroidal iodine content (TIC) with an improved measuring system. Exp Clin Endocrinol Diabetes 1997; 106 (Supp 3): 31-33.
19. Richtlinie Strahlenschutz in der Medizin 2002. Richtlinie nach der Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (Strahlenschutzverordnung - StrlSchV). Ausgabe mit ausführlichem Erläuterungsteil 5. Aufl./Kemmer W, Michalczak H. Berlin: H. Hoffmann 2003; 49-58.
20. Rink T, Bormuth F-J, Schroth H-J et al. Spectrometric assessment of thyroid depth within the radioiodine test. Nuklearmedizin 2005; 44: 192-196.
21. Sabri O, Schulz G, Zimny M et al. Bestimmung von Einflussgröß en für den Erfolg der Radioiodtherapie bei Patienten mit Morbus Basedow. Nuklearmedizin 1998; 37: 83-89.
22. Sabri O, Zimny M, Schreckenberger M et al. Characteristics of radioiodine therapy failures in Graves' disease. Nuklearmedizin 2001; 40: 1-6.
23. Schaffhauser K, Hänscheid H, Rendl J et al. Intrathyroidal iodine concentration after application of non-ionic contrast media with and without prophylactic application of perchlorate. Nuklearmedizin 2005; 44: 143-148.
24. Urbannek V, Schmidt M, Moka D et al. Influence of iodine application during radioiodine therapy in case of impending therapy failure. Nuklearmedizin 2000; 39: 108-112.
25. Vogt H, Wengenmair H, Kopp J et al. Radioiodine therapy for combined disseminated and nodular thyroid autonomy. Nuklearmedizin 2006; 45: 101-104.
26. Walter MA, Christ-Crain M, Müller B et al. Radioiodine uptake and thyroid hormone levels on or off simultaneous carbimazole medication: A prospective paired comparison. Nuklearmedizin 2005; 44: 33-36.
27. Weber K, Wellner U, Voth E et al. Influence of stable iodine on the uptake of the thyroid - model versus experiment. Nuklearmedizin 2001; 40: 31-37.
28. Wellner U, Alef K, Schicha H. Der Einfluss physiologischer und pharmakologischer Iodmengen auf den Iod-131-Uptake der Schilddrüse - eine Modellrechnung. Nuklearmedizin 1996; 35: 251-263.
29. Zöphel K, Wunderlich G, Kopprasch C et al. Prädiktiver Wert der Thyreotropinrezeptor-Antikörper bei Bestimmung im TRAK-human-Assay der zweiten Generation nach Radioiodtherapie des Morbus Basedow. Nuklearmedizin 2003; 42:63-70.